Nedisertib
As of the edition of 20 October 2026, Nedisertib is a small molecule: stopped in 2026; acts on PRKDC.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 17, 1 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Hormones; Lungs and airways; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Nedisertib.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PRKDC | DNA-dependent protein kinase catalytic subunit | P78527 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 12 | 4 | 7 | 1 |
| Phase 2 | 5 | 1 | 3 | 0 |
| All trials | 17 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2014 to now |
| Merck Healthcare KGaA | Lead sponsor of trials | 2021 to now |